Mostrando 10 resultados de: 13
Filtros aplicados
Publisher
Pharmacogenomics(4)
Drug Metabolism and Drug Interactions(2)
Clinical neuropharmacology(1)
Drug Metabolism and Personalized Therapy(1)
European Neuropsychopharmacology(1)
Área temáticas
Farmacología y terapéutica(13)
Medicina y salud(6)
Enfermedades(5)
Bioquímica(2)
Problemas sociales y servicios a grupos(2)
Origen
scopus(13)
Clinical drug-drug interactions: Focus on venlafaxine
ReviewAbstract: Venlafaxine (VEN) is an antidepressant agent widely used nowadays as an alternative to selective serPalabras claves:Drug-drug interactions, pharmacodynamics, pharmacokinetics, VenlafaxineAutores:Adrián LLerena, Alves G., Falcao A.C., Magalhães P.Fuentes:scopusCYP2D6 poor metabolizer status might be associated with better response to risperidone treatment
ArticleAbstract: The variability in the antipsychotic response is, to some extent, genetically determined. Several stPalabras claves:CYP2D6, EFFECTIVENESS, MDR1, pharmacogenetics, Risperidone, SchizophreniaAutores:Abad-Santos F., Adrián LLerena, Almoguera B., Ayuso C., Baca-García E., Dal-Ré R., Dorado P., Fernandez-Piqueras J., Lopez-Castroman J., Riveiro-Alvarez R., Vaquero-Lorenzo C.Fuentes:scopusAllele and genotype frequencies of genes relevant to anti-epileptic drug therapy in Mexican-Mestizo healthy volunteers
ArticleAbstract: Aim: To determine allele and genotype frequencies of genes influencing anti-epileptic drug therapy iPalabras claves:ABCC2, anti-epileptics, CYP3A5, EPHX1, GABRA1, HNF4A, Mexican-Mestizo, NR1I2, pharmacogenetics, RALBP1, SCN1A, SCN2A, UGT1A1, UGT2B7Autores:Adrián LLerena, Dorado P., Fricke-Galindo I., Jung-Cook H., López-López M., Monroy-Jaramillo N., Ortega-Vázquez A., Penãs-Lledó E.M.Fuentes:scopusAn International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels
ReviewAbstract: This international guideline proposes improving clozapine package inserts worldwide by using ancestrPalabras claves:American continental ancestry group, Asian continental ancestry group, clozapine/adverse effects, clozapine/blood, clozapine/metabolism, clozapine/therapeutic use, clozapine/toxicity, CYP1A2, drug labeling, European continental ancestry group, infection, inflammation, mortality/drug effects, Native, Sex, smoking.Autores:Adebayo R.A., Adrián LLerena, Anll Yaǧcloǧlu A.E., Arrojo-Romero M., Ayub M., Baptista T., Bebawi E., Bhattacharya R., Bilbily J., Bonelli R.M., Bousman C.A., Buckley P.F., Celofiga A., Chan S.K.W., Chopra N., Cohen D., Cotes R.O., Crespo-Facorro B., Cubała W.J., De Berardis D., De Las Cuevas C., De Leon J., Decloedt E., Eap C.B., Elkis H., Ertuǧrul A., Every-Palmer S., Farooq S., Fernandez-Egea E., Fountoulakis K.N., González-Esquivel D.F., Grover S., Gründer G., Hiemke C., Iglesias-Alonso A., Iglesias-Garcia C., Ignjatovic Ristic D., Jung-Cook H., Kaithi A.R., Kane J.M., Kelly D.L., Kim S.H., Kim Y.S., Kirilochev O.O., Kopeček M., Lana F., Lane H.Y., Lazary J., Leung J.G., Lin S.K., López-Jaramillo C., Marder S.R., Masmoudi R., McCollum B., McGrane I., Mohd Saffian S., Molden E., Motuca M., Ng C.H., Nielsen J., Olmos I., Ortiz B.B., Otsuka Y., Ouanes S., Pacheco Palha A.J., Pedro M.R., Procyshyn R.M., Quiles C., Rǎdulescu F., Rajkumar A.P., Ricciardi C., Rohde C., Ruan C.J., Sagud M., Sanz E.J., Schoretsanitis G., Schulte P.F.J., Seifritz E., Seppälä N., Shelton C., Silva A., Siskind D., Smith R.L., Solismaa A., Soloviev A., Spina E., Švancer P., Takeuchi H., Tang Y.L., Temmingh H., Torres R., Tsukahara M., Verdoux H., Villagrán-Moreno J.M., Wang C.Y., Wang G., Weizman A., Wilkowska A., Yecora A., Zolezzi M.Fuentes:scopusGenetic factors in the metabolism of haloperidol.
ArticleAbstract:Palabras claves:Autores:Adrián LLerena, Bertilsson L., Dahl M.L., Ekqvist B.Fuentes:scopusEvaluating a newly developed pharmacogenetic array: Screening in a Spanish population
ArticleAbstract: Aims: How genes affect the response in a patient to a given medication is still poorly understood; tPalabras claves:accuracy, CYP2D6, PHARMAChip array ®, pharmacogenetics, sensitivity, SLC6A4, Specificity, successful genotyping rateAutores:Abad-Santos F., Adrián LLerena, Almoguera B., Ayuso C., Dal-Ré R., Dorado P., Fernandez-Piqueras J., Gomez-Dominguez B., Lopez-Rodriguez R., Riveiro-Alvarez R., Vaquero-Lorenzo C.Fuentes:scopusHigh-performance liquid chromatography method using ultraviolet detection for the quantification of aripiprazole and dehydroaripiprazole in psychiatric patients
ArticleAbstract: Background: Aripiprazole (ARI) is an antipsychotic drug that is metabolized to dehydroaripiprazole (Palabras claves:Aripiprazole, CYP2D6, Dehydroaripiprazole, High-performance liquid chromatography, Psychiatric patientsAutores:Adrián LLerena, de Andrés F., De la Rubia A., Dorado P., Gonz Ález A., Gonz Ález I., Naranjo M.E.G., Peñ As-Lledó E.Fuentes:scopusIntuitive pharmacogenetic dosing of risperidone according to CYP2D6 phenotype extrapolated from genotype in a cohort of first episode psychosis patients
ArticleAbstract: Risperidone (R) is the most prescribed antipsychotic drug for patients with a first episode of psychPalabras claves:Antipsychotic, CYP2D6, pharmacogenetics, pharmacokineticsAutores:Adrián LLerena, Aguilar E.J., Albacete A., Alonso-Solís A., Baeza I., Balanzá-Martínez V., Balbuena A., Barcones F., Bergé D., Bernardo E.G., Bernardo M., Bioque M., Bobes J., Boloc D., Butjosa A., Castro-Fornieles J., Contreras F., Coromina M., Corripio I., Cuadrado A.I., Cuesta M.J., de la Serna E., Dompablo M., Echevarría R.S., Fraile M.G., García-Portillo M.P., Gassó P., González-Pinto A., Jimenez E., Lafuente A., Landín-Romero R., Lobo A., López P., Martínez-Cengotitabengoa M., Mas S., Morales-Muñoz I., Olmeda M.S., Parellada M., Rabella M., Rodriguez N., Rodriguez-Jimenez R., Sáiz P.A., Saiz-Ruiz J., Sanjuán J., Sarró S., Torra M., Torrent C., Usall J., Vieta E., Zapata M.Fuentes:scopusPharmacogenetics of clinical response to risperidone
ReviewAbstract: Despite risperidones proven safety and efficacy, existing pharmacogenetic knowledge could be appliedPalabras claves:Biomarkers, Clinical outcome, pharmacogenetics, Risperidone, side effectsAutores:Adrián LLerena, Berecz R., Humberto Fariñas, Penãs-Lledó E.M., Süveges A.Fuentes:scopusPharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients
ArticleAbstract: This study investigated to what extent fluvoxamine affects the pharmacokinetics of thioridazine (THDPalabras claves:Autores:Adrián LLerena, Agúndez J.A.G., Benitez Rodriguez J., Berecz R., Carrillo J.A., Duran M., Herraiz A., Ramos S.Fuentes:scopus